Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - calciumgluconat (monohydrat) - injektionsvæske, opløsning - 100 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - alle andre terapeutiske produkter - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Danmark - dansk - SEGES Landbrug & Fødevarer

upl europe ltd. (tidligere: united phosphorus ltd.) - desmedipham, phenmedipham - suspensionskoncentrat - 80 g/l desmedipham; 80 g/l phenmedipham

Danmark - dansk - SEGES Landbrug & Fødevarer

dla agro a.m.b.a. - sprede-klæbemiddel - flydende middel - 1000 g/l sprede-klæbemiddel

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

exelgyn - misoprostol - tabletter - 400 mikrogram

Den Europæiske Union - dansk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Danmark - dansk - SEGES Landbrug & Fødevarer

dow agrosciences danmark a/s - isoxaben - flydende middel - 500 g/l isoxaben

Danmark - dansk - SEGES Landbrug & Fødevarer

upl europe ltd. (tidligere: united phosphorus ltd.) - napropamid - suspensionskoncentrat - 418,5 g/l napropamid

Danmark - dansk - SEGES Landbrug & Fødevarer

bayer a/s - prothioconazol, fluopyram, bixafen - emulsionskoncentrat - 130 g/l prothioconazol; 65 g/l fluopyram; 65 g/l bixafen

Den Europæiske Union - dansk - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.